^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Prostate Cancer: Systemic Therapy for M1 CRPC…First-line and subsequent treatment options...Atezolizumab/carboplatin/etoposide (category 3)
    Secondary therapy:
    carboplatin + etoposide oral